PRO CAR-202

N/A

Report date: 2025/07/08 10:33:48

Base Information

Drug NamePRO CAR-202

Drug Alias NamePRO CAR-202

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-STEAP1Interleukin 18 modulators

TargetsSix-transmembrane epithelial antigen of the prostate 1Interleukin 18

Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesFred Hutchinson Cancer Research Center

China Registration ClassN/A

Develop Information

Active CompaniesPromiCell Inc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms, Castration-Resistant

Inactive IndicationsN/A

Other Information

ATC CodeN/A